Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
National Taiwan University Hospital
Vascular indices predict liver cancer responsiveness to thalidomide
June 15th, 2005
Vascular indices predict liver cancer responsiveness to thalidomide. Researchers in Taiwan conducted a study "to prospectively evaluate the feasibility of using power Doppler ultrasonography (US) and measurement of circulating angiogenic factors to assess the antiangiogenic effect of thalidomide in hepatocellular carcinoma. The Ethics Committee of the National Taiwan University Hospital approved the study, and all patients gave prior written informed consent." "Evaluation of response to thalidomide treatment was based on findings at computed tomography (CT) and change in serum alpha-fetoprotein level. Tumor vascularity index was evaluated with power...
Source: Physician Law Weekly (2005-06-15)
|
